A Phase II Trial of the Combination of Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular NHL (RV 0163).

Trial Profile

A Phase II Trial of the Combination of Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular NHL (RV 0163).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Dec 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2018.
    • 20 Dec 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.
    • 24 Mar 2015 Planned End Date changed from 1 Jul 2015 to 1 Jan 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top